| Elizabeth C Goble, ACMHC | |
|
166 N 300 W, Suite 1, St George, UT 84770-2770 | |
| (435) 862-8273 | |
| Not Available |
| Full Name | Elizabeth C Goble |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 166 N 300 W, St George, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114232998 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 7099865-6009 (Utah) | Primary |
| Entity Name | Therapy Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578703468 PECOS PAC ID: 3173882065 Enrollment ID: O20180123001292 |
News Archive
Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.
Illumina, Inc. and Bio‑Rad Laboratories, Inc. today announced the launch of the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco.
ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.
"New research supported by Sightsavers and the African Programme for Onchocerciasis Control (APOC) shows that yes, onchocerciasis really can be eliminated when treatment is distributed in an area for a sustained period" and "found that the disease may already be eliminated in one Nigerian state, marking a significant milestone for onchocerciasis control programs," the Global Network for Neglected Diseases' "End the Neglect" blog writes.
BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth C Goble, ACMHC 166 N 300 W, Suite 1, St George, UT 84770-2770 Ph: (435) 862-8273 | Elizabeth C Goble, ACMHC 166 N 300 W, Suite 1, St George, UT 84770-2770 Ph: (435) 862-8273 |
News Archive
Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.
Illumina, Inc. and Bio‑Rad Laboratories, Inc. today announced the launch of the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco.
ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.
"New research supported by Sightsavers and the African Programme for Onchocerciasis Control (APOC) shows that yes, onchocerciasis really can be eliminated when treatment is distributed in an area for a sustained period" and "found that the disease may already be eliminated in one Nigerian state, marking a significant milestone for onchocerciasis control programs," the Global Network for Neglected Diseases' "End the Neglect" blog writes.
BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.
› Verified 3 days ago
Lukas Hildebrandt, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1067 E Tabernacle St Ste 7, St George, UT 84770 Phone: 801-255-5131 | |
Jan Hadlock, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1492 S Silicon Way Ste A, St George, UT 84770 Phone: 435-275-8911 | |
Andrew J Weibert, Counselor Medicare: Not Enrolled in Medicare Practice Location: 225 N Bluff St Ste 5, St George, UT 84770 Phone: 435-229-9177 | |
Jason Reynolds, Counselor Medicare: Not Enrolled in Medicare Practice Location: 348 E 600 S, St George, UT 84770 Phone: 435-705-7574 | |
Sarah Cowley, Counselor Medicare: Not Enrolled in Medicare Practice Location: 474 W 200 N, Suite 300, St George, UT 84770 Phone: 435-634-5621 Fax: 435-986-8700 | |
Kiley Shelly, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1067 E Tabernacle St, Suite 7, St George, UT 84770 Phone: 801-255-5131 Fax: 801-255-5131 | |
Samantha Montag, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1492 S Silicon Way Ste A, St George, UT 84770 Phone: 435-275-8911 |